From Rettsyndrome.org
With great excitement, we would like to congratulate Neuren Pharmaceuticals for being granted Orphan Drug Status for NNZ-2566, now known as Trofinetide, for Rett Syndrome by the FDA. With the existing Fast Track Status, the Orphan Drug Status allows Neuren additional privileges under the Drug Act of 1983. Thank you to our donors and families, as well as Cure Rett for their continued partnership in helping to make this possible!
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.02 |
Change
-0.260(1.82%) |
Mkt cap ! $1.745B | |||
| Open | High | Low | Value | Volume |
| $14.44 | $14.44 | $14.00 | $3.454M | 245.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 7440 | $14.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.11 | 3159 | 1 |
View Market Depth
| Last trade - 16.10pm 07/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |